B2BROKER Introduces PrimeXM XCore Support & Maintenance Services for Brokers
19.2.2025 12:56:00 CET | Business Wire | Press release
B2BROKER has announced the launch of its PrimeXM XCore support and maintenance services, expanding its suite of technology solutions for brokers and financial institutions. This new solution complements the company’s existing support offerings for trading platforms, including cTrader, MT4, and MT5.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217935952/en/
B2BROKER's PrimeXM XCore Service provides complete support to manage all technical aspects, including setup and ongoing maintenance, of the PrimeXM XCore server. (Graphic: Business Wire)
PrimeXM XCore in the Trading Industry
PrimeXM’s XCore is a widely used trading and aggregation engine, serving over 250 financial institutions worldwide. It provides ultra-low latency order execution, risk management capabilities, and advanced reporting tools while supporting multi-asset trading across multiple venues.
As a key component in modern brokerage infrastructure, XCore offers brokers improved liquidity access and streamlined execution. However, maintaining and managing the system can be resource-intensive, often requiring the recruitment and training of specialised personnel. Establishing an in-house team to operate XCore typically involves significant time and financial investment.
B2BROKER’s Managed PrimeXM XCore Services
Recognising the operational challenges, B2BROKER has introduced a fully managed PrimeXM XCore service designed to reduce brokers' workloads.
The new service ensures that industry professionals handle all technical aspects of the system, from setup to ongoing maintenance. This allows brokers to focus on business development and client service.
Additionally, B2BROKER introduces a dedicated audit service for clients with an existing PrimeXM server. This service involves a thorough assessment of the setup and detailed recommendations to optimise system performance and ensure a seamless transition under the company’s maintenance.
Arthur Azizov, CEO and Founder of B2BROKER, says:
"We provide comprehensive support to manage all technical aspects of PrimeXM XCore, including setup, ongoing maintenance, and day-to-day operations. No matter the number or type of liquidity providers a broker works with, B2BROKER guarantees seamless trading operations."
Clive Diethelm, CEO and Founder of PrimeXM, comments:
"By collaborating with B2BROKER, we aim to enhance our offerings with flexible support models, ensuring clients can choose solutions that best fit their requirements."
Key Features of the Service
The service package provided by B2BROKER includes:
- Comprehensive System Configuration – Full setup of trading infrastructure, including instruments, asset classes, and user access management.
- Secure Connectivity – Secure and stable integration with liquidity providers and trading venues to ensure seamless execution.
- Customisable Trading Parameters – Adaptation of trading and routing rules to align with each broker’s operational model.
- Continuous Monitoring & Support – 24/7 system oversight to maintain stability and rapid issue resolution.
- Automated Performance Reports – Generation of daily and monthly reports offering insights into system performance and trading efficiency.
Summary
By introducing this service, B2BROKER aims to simplify technical management for brokers relying on PrimeXM XCore. The fully managed approach reduces operational complexities, minimises costs associated with in-house maintenance, and ensures uninterrupted trading operations.
For brokers seeking a reliable and efficient way to manage their PrimeXM XCore infrastructure, B2BROKER’s new service provides a structured solution backed by industry expertise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250217935952/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom